VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment

Wouter B Nagengast; Marjolijn N Lub-de Hooge; Sjoukje F Oosting; Wilfred F A den Dunnen; Frank-Jan Warnders; Adrienne H Brouwers; Patricia M Price; Harry Hollema; Geke A P Hospers; Philip H Elsinga; Jan Willem Hesselink; Jourik A Gietema; Elisabeth G de Vries

doi:10.1158/0008-5472.CAN-10-1088

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment

Wouter B Nagengast, Marjolijn N Lub-de Hooge, Sjoukje F Oosting, Wilfred F A den Dunnen, Frank-Jan Warnders, Adrienne H Brouwers, Patricia M Price, Harry Hollema, Geke A P Hospers, Philip H Elsinga, Jan Willem Hesselink, Jourik A Gietema, Elisabeth G de Vries

University Medical Center Groningen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Non-invasive imaging of angiogenesis could ease the optimization of antiangiogenesis treatments for cancer. In this study, we evaluated the role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib. The effects of sunitinib treatment and withdrawal on the tumor was investigated using the new VEGF-PET tracer (89)Zr-ranibizumab as well as (18)F-FDG PET, and (15)O-water PET in mouse xenograft models of human cancer. The obtained imaging results were compared with tumor growth, VEGF plasma levels and immunohistologic analyzes. In contrast to (18)F-FDG and (15)O-water PET, VEGF-PET demonstrated dynamic changes during sunitinib treatment within the tumor with a strong decline in signal in the tumor center and only minimal reduction in tumor rim, with a pronounced rebound after sunitinib discontinuation. VEGF-PET results corresponded with tumor growth and immunohistochemical vascular- and tumor- markers. Our findings highlight the strengths of VEGF-PET imaging to allow serial analysis of angiogenic changes in different areas within a tumor.

Original language	English
Pages (from-to)	143-53
Number of pages	11
Journal	Cancer Research
Volume	71
Issue number	1
DOIs	https://doi.org/10.1158/0008-5472.CAN-10-1088
Publication status	Published - 1 Jan 2011

Keywords

Angiogenesis Inhibitors
Animals
Antineoplastic Agents
Biomarkers, Tumor
Fluorodeoxyglucose F18
Humans
Indoles
Male
Mice
Mice, Nude
Positron-Emission Tomography
Pyrroles
Transplantation, Heterologous
Vascular Endothelial Growth Factor A
Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/0008-5472.CAN-10-1088

Cite this

Nagengast, W. B., Lub-de Hooge, M. N., Oosting, S. F., den Dunnen, W. F. A., Warnders, F.-J., Brouwers, A. H., Price, P. M., Hollema, H., Hospers, G. A. P., Elsinga, P. H., Hesselink, J. W., Gietema, J. A., & de Vries, E. G. (2011). VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Research, 71(1), 143-53. https://doi.org/10.1158/0008-5472.CAN-10-1088

@article{e56b3c4e860a4e4b95dc53e5aec4794c,

title = "VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment",

abstract = "Non-invasive imaging of angiogenesis could ease the optimization of antiangiogenesis treatments for cancer. In this study, we evaluated the role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib. The effects of sunitinib treatment and withdrawal on the tumor was investigated using the new VEGF-PET tracer (89)Zr-ranibizumab as well as (18)F-FDG PET, and (15)O-water PET in mouse xenograft models of human cancer. The obtained imaging results were compared with tumor growth, VEGF plasma levels and immunohistologic analyzes. In contrast to (18)F-FDG and (15)O-water PET, VEGF-PET demonstrated dynamic changes during sunitinib treatment within the tumor with a strong decline in signal in the tumor center and only minimal reduction in tumor rim, with a pronounced rebound after sunitinib discontinuation. VEGF-PET results corresponded with tumor growth and immunohistochemical vascular- and tumor- markers. Our findings highlight the strengths of VEGF-PET imaging to allow serial analysis of angiogenic changes in different areas within a tumor.",

keywords = "Angiogenesis Inhibitors, Animals, Antineoplastic Agents, Biomarkers, Tumor, Fluorodeoxyglucose F18, Humans, Indoles, Male, Mice, Mice, Nude, Positron-Emission Tomography, Pyrroles, Transplantation, Heterologous, Vascular Endothelial Growth Factor A, Journal Article, Research Support, Non-U.S. Gov't",

author = "Nagengast, {Wouter B} and {Lub-de Hooge}, {Marjolijn N} and Oosting, {Sjoukje F} and {den Dunnen}, {Wilfred F A} and Frank-Jan Warnders and Brouwers, {Adrienne H} and Price, {Patricia M} and Harry Hollema and Hospers, {Geke A P} and Elsinga, {Philip H} and Hesselink, {Jan Willem} and Gietema, {Jourik A} and {de Vries}, {Elisabeth G}",

note = "{\textcopyright} 2010 AACR.",

year = "2011",

month = jan,

day = "1",

doi = "10.1158/0008-5472.CAN-10-1088",

language = "English",

volume = "71",

pages = "143--53",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

Nagengast, WB, Lub-de Hooge, MN, Oosting, SF, den Dunnen, WFA, Warnders, F-J, Brouwers, AH, Price, PM, Hollema, H, Hospers, GAP, Elsinga, PH, Hesselink, JW, Gietema, JA & de Vries, EG 2011, 'VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment', Cancer Research, vol. 71, no. 1, pp. 143-53. https://doi.org/10.1158/0008-5472.CAN-10-1088

TY - JOUR

T1 - VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment

AU - Nagengast, Wouter B

AU - Lub-de Hooge, Marjolijn N

AU - Oosting, Sjoukje F

AU - den Dunnen, Wilfred F A

AU - Warnders, Frank-Jan

AU - Brouwers, Adrienne H

AU - Price, Patricia M

AU - Hollema, Harry

AU - Hospers, Geke A P

AU - Elsinga, Philip H

AU - Hesselink, Jan Willem

AU - Gietema, Jourik A

AU - de Vries, Elisabeth G

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Non-invasive imaging of angiogenesis could ease the optimization of antiangiogenesis treatments for cancer. In this study, we evaluated the role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib. The effects of sunitinib treatment and withdrawal on the tumor was investigated using the new VEGF-PET tracer (89)Zr-ranibizumab as well as (18)F-FDG PET, and (15)O-water PET in mouse xenograft models of human cancer. The obtained imaging results were compared with tumor growth, VEGF plasma levels and immunohistologic analyzes. In contrast to (18)F-FDG and (15)O-water PET, VEGF-PET demonstrated dynamic changes during sunitinib treatment within the tumor with a strong decline in signal in the tumor center and only minimal reduction in tumor rim, with a pronounced rebound after sunitinib discontinuation. VEGF-PET results corresponded with tumor growth and immunohistochemical vascular- and tumor- markers. Our findings highlight the strengths of VEGF-PET imaging to allow serial analysis of angiogenic changes in different areas within a tumor.

AB - Non-invasive imaging of angiogenesis could ease the optimization of antiangiogenesis treatments for cancer. In this study, we evaluated the role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib. The effects of sunitinib treatment and withdrawal on the tumor was investigated using the new VEGF-PET tracer (89)Zr-ranibizumab as well as (18)F-FDG PET, and (15)O-water PET in mouse xenograft models of human cancer. The obtained imaging results were compared with tumor growth, VEGF plasma levels and immunohistologic analyzes. In contrast to (18)F-FDG and (15)O-water PET, VEGF-PET demonstrated dynamic changes during sunitinib treatment within the tumor with a strong decline in signal in the tumor center and only minimal reduction in tumor rim, with a pronounced rebound after sunitinib discontinuation. VEGF-PET results corresponded with tumor growth and immunohistochemical vascular- and tumor- markers. Our findings highlight the strengths of VEGF-PET imaging to allow serial analysis of angiogenic changes in different areas within a tumor.

KW - Angiogenesis Inhibitors

KW - Animals

KW - Antineoplastic Agents

KW - Biomarkers, Tumor

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Indoles

KW - Male

KW - Mice

KW - Mice, Nude

KW - Positron-Emission Tomography

KW - Pyrroles

KW - Transplantation, Heterologous

KW - Vascular Endothelial Growth Factor A

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1158/0008-5472.CAN-10-1088

DO - 10.1158/0008-5472.CAN-10-1088

M3 - Article

C2 - 21084271

SN - 0008-5472

VL - 71

SP - 143

EP - 153

JO - Cancer Research

JF - Cancer Research

IS - 1

ER -

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this